Literature DB >> 6770995

Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones.

F L Meyskens, B B Fuller.   

Abstract

The effect of four different retinoids [retinol, 13-cis-retinoic acid (Ro4-3780), beta-all-trans-retinoic acid, and aromatic retinoic acid ethyl ester (Ro10-9359)] on the cellular proliferation (cell number) and biochemical differentiation (tyrosinase activity) of a human melanoma cell line (MIRW) and three subclones was assessed. All four retinoids (10(-6) M) inhibited the cellular proliferation (36 to 42%) and stimulated tyrosinase activity (58 to 72%) in the parent cell line to a similar extent. In contrast, the effects of the different retinoids on three derived melanoma clones was dissimilar. For example, in clone A6, beta-all-transretinoic acid stimulated tyrosinase activity by 48% but caused only a 7% inhibition of cellular proliferation. This retinoid caused a more pronounced effect in the other two subclones, stimulating tyrosinase from 135 to 195% and inhibiting growth 19 to 33%. Al three melanoma clones demonstrated increased tyrosinase activity (110 to 225%) and reduced proliferation (37 to 52%) following exposure to 13-cis-retinoic acid. This retinoid was found overall to be the most effective stimulator of tyrosinase, while retinol was observed to be the least active, stimulating enzyme activity slightly (25%) in only one of three clones. Retinol inhibited proliferation 27 to 33% in two of three melanoma subclones. The aromatic retinoic acid ethyl ester elevated tyrosinase levels in two clones but inhibited the enzyme in one melanoma line. Cellular proliferation, however, was reduced in all three clones. These results suggest that retinoid-induced changes in human melanoma cell growth and differentiation reflect underlying cellular differences and diverse biochemical interactions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770995

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Limitations of the quantitative cytochemical assay of catechol oxidase in melanoma cells.

Authors:  A C Croce; G Bottiroli; E Prosperi; R Supino; P J Stoward
Journal:  Histochem J       Date:  1988-11

Review 2.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

3.  Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap.

Authors:  V Graham; E S Surwit; S Weiner; F L Meyskens
Journal:  West J Med       Date:  1986-08

Review 4.  Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

5.  Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines.

Authors:  M Haussler; N Sidell; M Kelly; C Donaldson; A Altman; D Mangelsdorf
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

6.  Association of vitamin A and carotenoid intake with melanoma risk in a large prospective cohort.

Authors:  Maryam M Asgari; Theodore M Brasky; Emily White
Journal:  J Invest Dermatol       Date:  2012-03-01       Impact factor: 8.551

7.  Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo.

Authors:  D Schadendorf; M A Kern; M Artuc; H L Pahl; T Rosenbach; I Fichtner; W Nürnberg; S Stüting; E von Stebut; M Worm; A Makki; K Jurgovsky; G Kolde; B M Henz
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

8.  Modulation of clonogenic human melanoma cells by follicle-stimulating hormone, melatonin, and nerve growth factor.

Authors:  F L Meyskens; S E Salmon
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

9.  Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.

Authors:  R Supino; E Prosperi; F Formelli; M Mariani; G Parmiani
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.